img

Global Acquired Immunodeficiency Syndrome Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Acquired Immunodeficiency Syndrome Market Insights, Forecast to 2034

Acquired immunodeficiency syndrome (AIDS) is one of the most widespread, catastrophic, and incurable diseases among humans in the world. According to a report published by the World Health Organization (WHO) in 2013, deaths caused by HIV ranked sixth in the total number of deaths in the world. Human immunodeficiency virus (HIV) presents itself as a complex mixture of symptoms, all related to severe immune compromise, while AIDS is an advanced stage of HIV infection.
Market Analysis and InsightsGlobal Acquired Immunodeficiency Syndrome Market
Global Acquired Immunodeficiency Syndrome market is expected to reach to US$ 1587 million in 2024, with a positive growth of %, compared with US$ 1536 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Acquired Immunodeficiency Syndrome industry is evaluated to reach US$ 1962.2 million in 2029. The CAGR will be 3.6% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Acquired Immunodeficiency Syndrome market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Acquired Immunodeficiency Syndrome market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Takeda
AstraZeneca Eli Lilly and Company
Merck KGaA
Sanofi
Pfizer
Amgen
Biogen
Novartis
Actelion
Daiichi Sankyo Company
Segment by Type
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Segment by Application


Hospital Pharmacy
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Acquired Immunodeficiency Syndrome introduction, etc. Acquired Immunodeficiency Syndrome Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Acquired Immunodeficiency Syndrome
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
1.2.3 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.3 Market by Application
1.3.1 Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acquired Immunodeficiency Syndrome Market Perspective (2018-2029)
2.2 Global Acquired Immunodeficiency Syndrome Growth Trends by Region
2.2.1 Acquired Immunodeficiency Syndrome Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Acquired Immunodeficiency Syndrome Historic Market Size by Region (2018-2024)
2.2.3 Acquired Immunodeficiency Syndrome Forecasted Market Size by Region (2024-2029)
2.3 Acquired Immunodeficiency Syndrome Market Dynamics
2.3.1 Acquired Immunodeficiency Syndrome Industry Trends
2.3.2 Acquired Immunodeficiency Syndrome Market Drivers
2.3.3 Acquired Immunodeficiency Syndrome Market Challenges
2.3.4 Acquired Immunodeficiency Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Acquired Immunodeficiency Syndrome by Players
3.1.1 Global Acquired Immunodeficiency Syndrome Revenue by Players (2018-2024)
3.1.2 Global Acquired Immunodeficiency Syndrome Revenue Market Share by Players (2018-2024)
3.2 Global Acquired Immunodeficiency Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Acquired Immunodeficiency Syndrome, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Acquired Immunodeficiency Syndrome Market Concentration Ratio
3.4.1 Global Acquired Immunodeficiency Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acquired Immunodeficiency Syndrome Revenue in 2022
3.5 Global Key Players of Acquired Immunodeficiency Syndrome Head office and Area Served
3.6 Global Key Players of Acquired Immunodeficiency Syndrome, Product and Application
3.7 Global Key Players of Acquired Immunodeficiency Syndrome, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Acquired Immunodeficiency Syndrome Breakdown Data by Type
4.1 Global Acquired Immunodeficiency Syndrome Historic Market Size by Type (2018-2024)
4.2 Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Type (2024-2029)
5 Acquired Immunodeficiency Syndrome Breakdown Data by Application
5.1 Global Acquired Immunodeficiency Syndrome Historic Market Size by Application (2018-2024)
5.2 Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Acquired Immunodeficiency Syndrome Market Size (2018-2029)
6.2 North America Acquired Immunodeficiency Syndrome Market Size by Type
6.2.1 North America Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024)
6.2.2 North America Acquired Immunodeficiency Syndrome Market Size by Type (2024-2029)
6.2.3 North America Acquired Immunodeficiency Syndrome Market Share by Type (2018-2029)
6.3 North America Acquired Immunodeficiency Syndrome Market Size by Application
6.3.1 North America Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024)
6.3.2 North America Acquired Immunodeficiency Syndrome Market Size by Application (2024-2029)
6.3.3 North America Acquired Immunodeficiency Syndrome Market Share by Application (2018-2029)
6.4 North America Acquired Immunodeficiency Syndrome Market Size by Country
6.4.1 North America Acquired Immunodeficiency Syndrome Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Acquired Immunodeficiency Syndrome Market Size by Country (2018-2024)
6.4.3 North America Acquired Immunodeficiency Syndrome Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Acquired Immunodeficiency Syndrome Market Size (2018-2029)
7.2 Europe Acquired Immunodeficiency Syndrome Market Size by Type
7.2.1 Europe Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024)
7.2.2 Europe Acquired Immunodeficiency Syndrome Market Size by Type (2024-2029)
7.2.3 Europe Acquired Immunodeficiency Syndrome Market Share by Type (2018-2029)
7.3 Europe Acquired Immunodeficiency Syndrome Market Size by Application
7.3.1 Europe Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024)
7.3.2 Europe Acquired Immunodeficiency Syndrome Market Size by Application (2024-2029)
7.3.3 Europe Acquired Immunodeficiency Syndrome Market Share by Application (2018-2029)
7.4 Europe Acquired Immunodeficiency Syndrome Market Size by Country
7.4.1 Europe Acquired Immunodeficiency Syndrome Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Acquired Immunodeficiency Syndrome Market Size by Country (2018-2024)
7.4.3 Europe Acquired Immunodeficiency Syndrome Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Acquired Immunodeficiency Syndrome Market Size (2018-2029)
8.2 China Acquired Immunodeficiency Syndrome Market Size by Type
8.2.1 China Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024)
8.2.2 China Acquired Immunodeficiency Syndrome Market Size by Type (2024-2029)
8.2.3 China Acquired Immunodeficiency Syndrome Market Share by Type (2018-2029)
8.3 China Acquired Immunodeficiency Syndrome Market Size by Application
8.3.1 China Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024)
8.3.2 China Acquired Immunodeficiency Syndrome Market Size by Application (2024-2029)
8.3.3 China Acquired Immunodeficiency Syndrome Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Acquired Immunodeficiency Syndrome Market Size (2018-2029)
9.2 Asia Acquired Immunodeficiency Syndrome Market Size by Type
9.2.1 Asia Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024)
9.2.2 Asia Acquired Immunodeficiency Syndrome Market Size by Type (2024-2029)
9.2.3 Asia Acquired Immunodeficiency Syndrome Market Share by Type (2018-2029)
9.3 Asia Acquired Immunodeficiency Syndrome Market Size by Application
9.3.1 Asia Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024)
9.3.2 Asia Acquired Immunodeficiency Syndrome Market Size by Application (2024-2029)
9.3.3 Asia Acquired Immunodeficiency Syndrome Market Share by Application (2018-2029)
9.4 Asia Acquired Immunodeficiency Syndrome Market Size by Region
9.4.1 Asia Acquired Immunodeficiency Syndrome Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Acquired Immunodeficiency Syndrome Market Size by Region (2018-2024)
9.4.3 Asia Acquired Immunodeficiency Syndrome Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Type
10.2.1 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Application
10.3.1 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Country
10.4.1 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Details
11.1.2 Takeda Business Overview
11.1.3 Takeda Acquired Immunodeficiency Syndrome Introduction
11.1.4 Takeda Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024)
11.1.5 Takeda Recent Developments
11.2 AstraZeneca Eli Lilly and Company
11.2.1 AstraZeneca Eli Lilly and Company Company Details
11.2.2 AstraZeneca Eli Lilly and Company Business Overview
11.2.3 AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Introduction
11.2.4 AstraZeneca Eli Lilly and Company Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024)
11.2.5 AstraZeneca Eli Lilly and Company Recent Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Details
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Acquired Immunodeficiency Syndrome Introduction
11.3.4 Merck KGaA Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024)
11.3.5 Merck KGaA Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Acquired Immunodeficiency Syndrome Introduction
11.4.4 Sanofi Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024)
11.4.5 Sanofi Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Acquired Immunodeficiency Syndrome Introduction
11.5.4 Pfizer Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024)
11.5.5 Pfizer Recent Developments
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Acquired Immunodeficiency Syndrome Introduction
11.6.4 Amgen Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024)
11.6.5 Amgen Recent Developments
11.7 Biogen
11.7.1 Biogen Company Details
11.7.2 Biogen Business Overview
11.7.3 Biogen Acquired Immunodeficiency Syndrome Introduction
11.7.4 Biogen Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024)
11.7.5 Biogen Recent Developments
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Acquired Immunodeficiency Syndrome Introduction
11.8.4 Novartis Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024)
11.8.5 Novartis Recent Developments
11.9 Actelion
11.9.1 Actelion Company Details
11.9.2 Actelion Business Overview
11.9.3 Actelion Acquired Immunodeficiency Syndrome Introduction
11.9.4 Actelion Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024)
11.9.5 Actelion Recent Developments
11.10 Daiichi Sankyo Company
11.10.1 Daiichi Sankyo Company Company Details
11.10.2 Daiichi Sankyo Company Business Overview
11.10.3 Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Introduction
11.10.4 Daiichi Sankyo Company Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024)
11.10.5 Daiichi Sankyo Company Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Table 3. Key Players of Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 4. Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Acquired Immunodeficiency Syndrome Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Acquired Immunodeficiency Syndrome Market Size by Region (2018-2024) & (US$ Million)
Table 7. Global Acquired Immunodeficiency Syndrome Market Share by Region (2018-2024)
Table 8. Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Acquired Immunodeficiency Syndrome Market Share by Region (2024-2029)
Table 10. Acquired Immunodeficiency Syndrome Market Trends
Table 11. Acquired Immunodeficiency Syndrome Market Drivers
Table 12. Acquired Immunodeficiency Syndrome Market Challenges
Table 13. Acquired Immunodeficiency Syndrome Market Restraints
Table 14. Global Acquired Immunodeficiency Syndrome Revenue by Players (2018-2024) & (US$ Million)
Table 15. Global Acquired Immunodeficiency Syndrome Revenue Share by Players (2018-2024)
Table 16. Global Top Acquired Immunodeficiency Syndrome by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acquired Immunodeficiency Syndrome as of 2022)
Table 17. Global Acquired Immunodeficiency Syndrome Industry Ranking 2021 VS 2022 VS 2024
Table 18. Global 5 Largest Players Market Share by Acquired Immunodeficiency Syndrome Revenue (CR5 and HHI) & (2018-2024)
Table 19. Global Key Players of Acquired Immunodeficiency Syndrome, Headquarters and Area Served
Table 20. Global Key Players of Acquired Immunodeficiency Syndrome, Product and Application
Table 21. Global Key Players of Acquired Immunodeficiency Syndrome, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024) & (US$ Million)
Table 24. Global Acquired Immunodeficiency Syndrome Revenue Market Share by Type (2018-2024)
Table 25. Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Acquired Immunodeficiency Syndrome Revenue Market Share by Type (2024-2029)
Table 27. Global Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024) & (US$ Million)
Table 28. Global Acquired Immunodeficiency Syndrome Revenue Share by Application (2018-2024)
Table 29. Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Acquired Immunodeficiency Syndrome Revenue Share by Application (2024-2029)
Table 31. North America Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024) & (US$ Million)
Table 32. North America Acquired Immunodeficiency Syndrome Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024) & (US$ Million)
Table 34. North America Acquired Immunodeficiency Syndrome Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Acquired Immunodeficiency Syndrome Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Acquired Immunodeficiency Syndrome Market Size by Country (2018-2024) & (US$ Million)
Table 37. North America Acquired Immunodeficiency Syndrome Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024) & (US$ Million)
Table 39. Europe Acquired Immunodeficiency Syndrome Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024) & (US$ Million)
Table 41. Europe Acquired Immunodeficiency Syndrome Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Acquired Immunodeficiency Syndrome Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Acquired Immunodeficiency Syndrome Market Size by Country (2018-2024) & (US$ Million)
Table 44. Europe Acquired Immunodeficiency Syndrome Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024) & (US$ Million)
Table 46. China Acquired Immunodeficiency Syndrome Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024) & (US$ Million)
Table 48. China Acquired Immunodeficiency Syndrome Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024) & (US$ Million)
Table 50. Asia Acquired Immunodeficiency Syndrome Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024) & (US$ Million)
Table 52. Asia Acquired Immunodeficiency Syndrome Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Acquired Immunodeficiency Syndrome Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Acquired Immunodeficiency Syndrome Market Size by Region (2018-2024) & (US$ Million)
Table 55. Asia Acquired Immunodeficiency Syndrome Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Type (2018-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Application (2018-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Country (2018-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size by Country (2024-2029) & (US$ Million)
Table 63. Takeda Company Details
Table 64. Takeda Business Overview
Table 65. Takeda Acquired Immunodeficiency Syndrome Product
Table 66. Takeda Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024) & (US$ Million)
Table 67. Takeda Recent Developments
Table 68. AstraZeneca Eli Lilly and Company Company Details
Table 69. AstraZeneca Eli Lilly and Company Business Overview
Table 70. AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Product
Table 71. AstraZeneca Eli Lilly and Company Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024) & (US$ Million)
Table 72. AstraZeneca Eli Lilly and Company Recent Developments
Table 73. Merck KGaA Company Details
Table 74. Merck KGaA Business Overview
Table 75. Merck KGaA Acquired Immunodeficiency Syndrome Product
Table 76. Merck KGaA Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024) & (US$ Million)
Table 77. Merck KGaA Recent Developments
Table 78. Sanofi Company Details
Table 79. Sanofi Business Overview
Table 80. Sanofi Acquired Immunodeficiency Syndrome Product
Table 81. Sanofi Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024) & (US$ Million)
Table 82. Sanofi Recent Developments
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Acquired Immunodeficiency Syndrome Product
Table 86. Pfizer Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024) & (US$ Million)
Table 87. Pfizer Recent Developments
Table 88. Amgen Company Details
Table 89. Amgen Business Overview
Table 90. Amgen Acquired Immunodeficiency Syndrome Product
Table 91. Amgen Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024) & (US$ Million)
Table 92. Amgen Recent Developments
Table 93. Biogen Company Details
Table 94. Biogen Business Overview
Table 95. Biogen Acquired Immunodeficiency Syndrome Product
Table 96. Biogen Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024) & (US$ Million)
Table 97. Biogen Recent Developments
Table 98. Novartis Company Details
Table 99. Novartis Business Overview
Table 100. Novartis Acquired Immunodeficiency Syndrome Product
Table 101. Novartis Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024) & (US$ Million)
Table 102. Novartis Recent Developments
Table 103. Actelion Company Details
Table 104. Actelion Business Overview
Table 105. Actelion Acquired Immunodeficiency Syndrome Product
Table 106. Actelion Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024) & (US$ Million)
Table 107. Actelion Recent Developments
Table 108. Daiichi Sankyo Company Company Details
Table 109. Daiichi Sankyo Company Business Overview
Table 110. Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Product
Table 111. Daiichi Sankyo Company Revenue in Acquired Immunodeficiency Syndrome Business (2018-2024) & (US$ Million)
Table 112. Daiichi Sankyo Company Recent Developments
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Acquired Immunodeficiency Syndrome Market Share by Type: 2022 VS 2029
Figure 3. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Features
Figure 4. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Features
Figure 5. Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Acquired Immunodeficiency Syndrome Market Share by Application: 2022 VS 2029
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Others Case Studies
Figure 10. Acquired Immunodeficiency Syndrome Report Years Considered
Figure 11. Global Acquired Immunodeficiency Syndrome Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Acquired Immunodeficiency Syndrome Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Acquired Immunodeficiency Syndrome Market Share by Region: 2022 VS 2029
Figure 14. Global Acquired Immunodeficiency Syndrome Market Share by Players in 2022
Figure 15. Global Top Acquired Immunodeficiency Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acquired Immunodeficiency Syndrome as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Acquired Immunodeficiency Syndrome Revenue in 2022
Figure 17. North America Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Acquired Immunodeficiency Syndrome Market Share by Type (2018-2029)
Figure 19. North America Acquired Immunodeficiency Syndrome Market Share by Application (2018-2029)
Figure 20. North America Acquired Immunodeficiency Syndrome Market Share by Country (2018-2029)
Figure 21. United States Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Acquired Immunodeficiency Syndrome Market Size YoY (2018-2029) & (US$ Million)
Figure 24. Europe Acquired Immunodeficiency Syndrome Market Share by Type (2018-2029)
Figure 25. Europe Acquired Immunodeficiency Syndrome Market Share by Application (2018-2029)
Figure 26. Europe Acquired Immunodeficiency Syndrome Market Share by Country (2018-2029)
Figure 27. Germany Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. France Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. U.K. Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Italy Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Russia Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Nordic Countries Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. China Acquired Immunodeficiency Syndrome Market Size YoY (2018-2029) & (US$ Million)
Figure 34. China Acquired Immunodeficiency Syndrome Market Share by Type (2018-2029)
Figure 35. China Acquired Immunodeficiency Syndrome Market Share by Application (2018-2029)
Figure 36. Asia Acquired Immunodeficiency Syndrome Market Size YoY (2018-2029) & (US$ Million)
Figure 37. Asia Acquired Immunodeficiency Syndrome Market Share by Type (2018-2029)
Figure 38. Asia Acquired Immunodeficiency Syndrome Market Share by Application (2018-2029)
Figure 39. Asia Acquired Immunodeficiency Syndrome Market Share by Region (2018-2029)
Figure 40. Japan Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. South Korea Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. China Taiwan Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Southeast Asia Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. India Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Australia Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Size YoY (2018-2029) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Share by Type (2018-2029)
Figure 48. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Share by Application (2018-2029)
Figure 49. Middle East, Africa, and Latin America Acquired Immunodeficiency Syndrome Market Share by Country (2018-2029)
Figure 50. Brazil Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Mexico Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Turkey Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Israel Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. GCC Countries Acquired Immunodeficiency Syndrome Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Takeda Revenue Growth Rate in Acquired Immunodeficiency Syndrome Business (2018-2024)
Figure 57. AstraZeneca Eli Lilly and Company Revenue Growth Rate in Acquired Immunodeficiency Syndrome Business (2018-2024)
Figure 58. Merck KGaA Revenue Growth Rate in Acquired Immunodeficiency Syndrome Business (2018-2024)
Figure 59. Sanofi Revenue Growth Rate in Acquired Immunodeficiency Syndrome Business (2018-2024)
Figure 60. Pfizer Revenue Growth Rate in Acquired Immunodeficiency Syndrome Business (2018-2024)
Figure 61. Amgen Revenue Growth Rate in Acquired Immunodeficiency Syndrome Business (2018-2024)
Figure 62. Biogen Revenue Growth Rate in Acquired Immunodeficiency Syndrome Business (2018-2024)
Figure 63. Novartis Revenue Growth Rate in Acquired Immunodeficiency Syndrome Business (2018-2024)
Figure 64. Actelion Revenue Growth Rate in Acquired Immunodeficiency Syndrome Business (2018-2024)
Figure 65. Daiichi Sankyo Company Revenue Growth Rate in Acquired Immunodeficiency Syndrome Business (2018-2024)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries